DIACOMIT

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Croatia, Estonia, Finland, France, Ireland, Japan, Lithuania, Netherlands, Poland, Romania, South Africa, Spain, UK.

Active ingredients

The drug DIACOMIT contains one active pharmaceutical ingredient (API):

1	Stiripentol UNII R02XOT8V8I - STIRIPENTOL
	Stiripentol potentiates the efficacy of other anticonvulsants, such as carbamazepine, sodium valproate, phenytoin, phenobarbital and many benzodiazepines, as the result of pharmacokinetic interactions. The second effect of stiripentol is mainly based on metabolic inhibition of several isoenzymes, in particular CYP450 3A4 and 2C19, involved in the hepatic metabolism of other anti-epileptic medicines.
	Read more about Stiripentol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
DIACOMIT Capsule / Powder for suspension	MPI, US: SPL/PLR	FDA, National Drug Code (US)
DIACOMIT Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N03AX17	Stiripentol	N Nervous system → N03 Antiepileptics → N03A Antiepileptics → N03AX Other antiepileptics
Discover more medicines within N03AX17

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	12088F, 12103B, 12106E, 12107F
CA	Health Products and Food Branch	02398958, 02398966, 02398974
EE	Ravimiamet	1280045, 1280056, 1280067, 1280078, 1280089, 1280090, 1280102, 1280113, 1280124, 1280135, 1280146, 1280157, 1848944, 1848955, 1848966
ES	Centro de información online de medicamentos de la AEMPS	06367002, 06367005, 06367008, 06367011
FI	Lääkealan turvallisuus- ja kehittämiskeskus	029596, 029608, 029619, 029630
FR	Base de données publique des médicaments	61501691, 63431170, 64809018, 69581821
GB	Medicines & Healthcare Products Regulatory Agency	134030, 134033, 134038, 134043
JP	医薬品医療機器総合機構	1139011M1028, 1139011R1025, 1139011R2021
LT	Valstybinė vaistų kontrolės tarnyba	1027928, 1027929, 1027930, 1027931, 1027932, 1027933, 1027934, 1027935, 1027936, 1027937, 1027938, 1027939, 1092749
NL	Z-Index G-Standaard, PRK	88560, 88579, 88587, 88595
PL	Rejestru Produktów Leczniczych	100172979, 100172991, 100173000, 100173022, 100458903
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W51468001, W51468002, W51468003, W51470001, W51470002, W51470003, W51471001, W51471002, W51471003, W58592001, W58592002, W58592003
US	FDA, National Drug Code	68418-7939, 68418-7940, 68418-7941, 68418-7942
ZA	Health Products Regulatory Authority	55/2.5/0281, 55/2.5/0282, 55/2.5/0283, 55/2.5/0284